MedTrace Logo

Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy

NCT07516886 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-04-08

No results posted yet for this study

Summary

This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer.

No investigational interventions will be performed. All diagnostic procedures, follow-up assessments, and treatments will be conducted in accordance with standard clinical practice and established prostate cancer management guidelines. Participation in the study will not influence treatment decisions.

Conditions

  • Prostate Cancer (Post Prostatectomy)
  • Prostate Cancer (Adenocarcinoma)
  • Prostate Cancer (Diagnosis)
  • Prostate Specific Antigen
  • Radical Prostatectomy

Interventions

PROCEDURE

Radical Prostatectomy

Radical prostatectomy for the treatment of prostate cancer. Open retropubic, laparoscopic or robot-assisted.

Sponsors & Collaborators

  • Lithuanian University of Health Sciences

    lead OTHER

Principal Investigators

  • Daimantas Milonas, MD, PhD, Professor · Lietuvos sveikatos mokslų universitetas

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-22
Primary Completion
2039-07-31
Completion
2039-07-31

Countries

  • Lithuania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07516886 on ClinicalTrials.gov